Cardlytics, Inc.
Cardlytics, Inc. (CDLX) Financial Performance & Income Statement Overview
Analyze Cardlytics, Inc. (CDLX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Cardlytics, Inc. (CDLX) Income Statement & Financial Overview
Review Cardlytics, Inc. CDLX income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $61.90M | $74.00M | $67.06M | $69.64M |
| Cost of Revenue | $36.74M | $41.26M | $38.51M | $39.79M |
| Gross Profit | $25.16M | $32.73M | $28.55M | $29.85M |
| Gross Profit Ratio | $0.41 | $0.44 | $0.43 | $0.43 |
| R&D Expenses | $11.71M | $9.89M | $13.19M | $13.47M |
| SG&A Expenses | $26.53M | $25.11M | $25.24M | $30.18M |
| Operating Expenses | $39.24M | $41.05M | $177.10M | $51.31M |
| Total Costs & Expenses | $75.98M | $82.31M | $215.60M | $91.09M |
| Interest Income | $546000.00 | $677000.00 | $877000.00 | $872000.00 |
| Interest Expense | $2.38M | $2.37M | $2.36M | $2.43M |
| Depreciation & Amortization | $6.92M | $6.50M | $7.53M | $7.05M |
| EBITDA | -$3.98M | -$6.72M | -$135.30M | $5.23M |
| EBITDA Ratio | -$0.06 | -$0.09 | -$2.02 | $0.08 |
| Operating Income | -$14.08M | -$8.31M | -$148.55M | -$21.46M |
| Operating Income Ratio | -$0.23 | -$0.11 | -$2.22 | -$0.31 |
| Other Income/Expenses (Net) | $797000.00 | -$7.28M | $3.36M | $11.55M |
| Income Before Tax | -$13.28M | -$15.59M | -$145.18M | -$4.26M |
| Income Before Tax Ratio | -$0.21 | -$0.21 | -$2.17 | -$0.06 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $4.26M |
| Net Income | -$13.28M | -$15.59M | -$145.18M | -$4.26M |
| Net Income Ratio | -$0.21 | -$0.21 | -$2.17 | -$0.06 |
| EPS | -$0.26 | -$0.31 | -$2.90 | -$0.09 |
| Diluted EPS | -$0.26 | -$0.31 | -$2.90 | -$0.09 |
| Weighted Avg Shares Outstanding | $51.86M | $51.005M | $50.03M | $49.06M |
| Weighted Avg Shares Outstanding (Diluted) | $51.86M | $51.005M | $50.03M | $49.06M |
The company's financials show resilient growth, with revenue advancing from $69.64M in Q2 2024 to $61.90M in Q1 2025. Gross profit remained healthy with margins at 41% in Q1 2025 compared to 43% in Q2 2024. Operating income hit -$14.08M last quarter, sustaining a consistent -23% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.98M. Net income rose to -$13.28M, while earnings per share reached -$0.26. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan